Trial Profile
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs Ondansetron (Primary)
- Indications Irritable bowel syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors RedHill Biopharma
- 28 Apr 2023 Results assessing the efficacy and safety of RHB-102 in patients with Irritable Bowel Syndrome-diarrhea-predominant, published in The American Journal of Gastroenterology.
- 01 Sep 2020 Results published in the American Journal of Gastroenterology
- 28 Jul 2020 Results published in RedHill Biopharma Media Release.